openPR Logo
Press release

Antisense Oligonucleotides Market Segmentation, Industry trends and Developments 2027

06-19-2018 11:27 AM CET | Health & Medicine

Press release from: Future Market Insights

Antisense Oligonucleotides Market Segmentation, Industry

Antisense oligonucleotides (ASOs) are 15–25 nt oligonucleotides designed to tie complementary RNA targets for the degradation. They are synthesized so that they can be used to block disease processes by altering the synthesis of a specific protein. ASOs offers promising treatment options for a range of medical disorders. They facilitate the development of therapeutics affecting protein targets which cannot be treated with protein therapeutics. They can target a particular malfunctioning gene, interfere with RNA function at cellular level, and can also be silenced or modulated. It allows modifications in immune system that facilitates treatment of a wide range of autoimmune disorders – that cannot be treated with available drugs. It is easy to scale up the commercial scale GMP production of these oligonucleotides compared to other biologic therapies. Moreover, the side effects of antisense oligonucleotides are minimal and can be controlled with ease as compared to other class of drugs.

View complete report: https://www.futuremarketinsights.com/reports/antisense-oligonucleotides-market

Though, the antisense oligonucleotides market has witnessed four FDA approvals [fomivirsen (Vitravene) approved in 1998 – which was discontinued due to low demand; pegaptanib (Macugen) in 2004; mipomersen (Kynamro) in 2013; and eteplirsen (Exondys 51) in 2016). However, this market is yet to achieve recognition as a valuable drug category like biologics, small molecules, and gene and cell therapy. However, in December 2016, this was projected to change with the approval of nusinersen (Spinraza) for treating spinal muscular atrophy (SMA), which is one of the most common genetic cause for infant mortality with no approved treatments. Spinraza has shown unprecedented results for the treatment of SMA in clinical trials.

Antisense Oligonucleotides Market: Drivers and Restraints

Strong pipeline of antisense oligonucleotides and increased focused on large number of product approvals and commercialization are some of the primary factors driving the growth of the global antisense oligonucleotides market. Moreover, significant advances in the field of antisense oligonucleotides at a therapeutic or clinical level is further contributing to the growth of the global antisense oligonucleotides market. However, the global antisense oligonucleotides market is grappling with numerous challenges related to diversity of oligonucleotides, delivery, and regulatory complexity. Despite several advancements at clinical levels, the delivering of active oligonucleotide to the actual site within target cells is still one of the major challenges hindering the growth of the global antisense oligonucleotides market. In addition to this, developing a new set of unique regulatory guidelines is another challenge limiting the growth of the global antisense oligonucleotides market.

A sample of this report is available upon request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-5377

Antisense Oligonucleotides Market: Segmentation

Tentatively, the global antisense oligonucleotides market has been segmented on the basis of drug, indication, end user and geography.

Based on drug, the global antisense oligonucleotides market is segmented as below:

Approved Drugs
Pegaptanib
Mipomersen
Eteplirsen
Pipeline Analysis

Based on indication, the global antisense oligonucleotides market is segmented as below:

Ocular Diseases
Cancer
Diabetes
Amyotrophic Lateral Sclerosis (ALS)
Duchenne Muscular Dystrophy
Spinal Muscular Atrophy
Others

To view TOC of this report is available upon request @ https://www.futuremarketinsights.com/toc/rep-gb-5377

Based on application, the global antisense oligonucleotides market is segmented as below:

Basic Research
Genomics
Target Validation
Drug Discovery
Antisense Oligonucleotides Market: Overview

Although the development of oligonucleotide therapeutics commenced in 1970s, FDA has approved only four oligonucleotide drugs (of which fomivirsen was discontinued) nearly a half century later. However, the filed is gaining momentum and is set to offer promising growth opportunities with a strong pipeline of 135 oligonucleotides in various stages of clinical trials. Even when the market performance of antisense oligonucleotides is not predictable as like other segments of the industry, the future looks very promising primarily reflected by the leadings players in the market and the amount of research and development investments.

Antisense Oligonucleotides Market: Regional Outlook

Geographically, the global antisense oligonucleotides market is segmented into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific excluding Japan, Japan, Middle East and Africa. North America clearly dominates the global antisense oligonucleotides market due to a strong product pipeline and increasing number of FDA approvals in the region.

Antisense Oligonucleotides Market: Key Players

Some of the players identified in the global antisense oligonucleotides market include Ionis Pharmaceuticals, Inc., Sarepta Therapeutics, Biogen, Alnylam Pharmaceuticals, Inc., Antisense Therapeutics Limited, Isarna Therapeutics GmbH, Arrowhead Pharmaceuticals, Inc., Atlantic Pharmaceuticals, Inc., Enzon Pharmaceuticals, Inc., Bio-Path Holdings, Inc., Gene Signal International SA, GlaxoSmithKline plc, Geron Corporation, Gradalis, ICO Therapeutics, Aptose Biosciences, Marina Biotech, miRagen Therapeutics, Inc., Synlogic, Inc., OncoGenex Pharmaceuticals Inc., Pharmaxis Ltd, Regulus Therapeutics Inc., Rexahn Pharmaceuticals, Inc., and RXi Pharmaceuticals, among others.

Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centres in the U.S. and India.

FMI’s research and consulting services help businesses around the globe navigate the challenges in a rapidly evolving marketplace with confidence and clarity. Our customised and syndicated market research reports deliver actionable insights that drive sustainable growth. We continuously track emerging trends and events in a broad range of end industries to ensure our clients prepare for the evolving needs of their consumers.

U.S. Office
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
Email: sales@futuremarketinsights.com
Web: https://www.futuremarketinsights.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Antisense Oligonucleotides Market Segmentation, Industry trends and Developments 2027 here

News-ID: 1087962 • Views:

More Releases from Future Market Insights

Polygon Mirror Scanner Motor Market Set to Hit USD 88.5 Million by 2035, Powered by Advanced Imaging and Office Tech
Polygon Mirror Scanner Motor Market Set to Hit USD 88.5 Million by 2035, Powered …
The global polygon mirror scanner motor market is experiencing robust growth, forecasted to rise from USD 55.9 million in 2025 to USD 88.5 million by 2035, which represents a nearly 1.6-fold increase over the assessment period. This remarkable expansion is shaped by the widespread adoption of next-generation scanning technologies and the rapid digital transformation across the printing and office equipment industries. As businesses renew their focus on speed, accuracy, and
Global p-Hydroxybenzoic Acid Market to Approach USD 400 Million by 2035, Driven by Polymer and Textile Demand
Global p-Hydroxybenzoic Acid Market to Approach USD 400 Million by 2035, Driven …
The global p-Hydroxybenzoic Acid (PHBA) market is entering a new era of growth, expected to rise from USD 213.0 million in 2025 to USD 399.8 million by 2035, showcasing a compound annual growth rate of 6.5%. This surge is underpinned by PHBA's flourishing adoption in polymer synthesis, textile processing, and supporting industries seeking high-performance and sustainable chemical solutions. As organizations shift towards advanced materials with enhanced durability, thermal stability, and
Sustainable Growth Drives Castor Oil Polyol Market to USD 418.8 Million by 2035 as Manufacturers Innovate for Green Industries
Sustainable Growth Drives Castor Oil Polyol Market to USD 418.8 Million by 2035 …
The castor oil polyol market is set to reshape the landscape of bio-based chemicals, growing from a value of USD 254.7 million in 2025 to USD 418.8 million by 2035. This represents a robust CAGR of 5.1% over the decade, with expansion driven by surging demand across chemical, automotive, construction, and coatings sectors. The market's early growth, spanning 2021 to 2025, reflects steady adoption as sustainable polyols substitute petroleum-based alternatives,
Global Fifth Wheel Coupling Market to Hit USD 1.2 Billion by 2035 Driven by Smart Fleet Innovations
Global Fifth Wheel Coupling Market to Hit USD 1.2 Billion by 2035 Driven by Smar …
The global Fifth Wheel Coupling Market continues to evolve as the logistics and transport sectors demand more efficient, safe, and smart towing systems. Valued at USD 547.3 million in 2020 and reaching USD 672.6 million by 2024, the market is projected to expand at a 6.0% CAGR from 2025 to 2035, ultimately achieving a valuation of USD 1,238.6 million. At the heart of this growth lies the critical role of fifth

All 5 Releases


More Releases for Antisense

Antisense Oligonucleotide Therapeutics Market
Antisense Oligonucleotide Therapeutics Market worth $ 64.64 Billion by 2030 - Exclusive Report by Insight Analytics Insight Analytics Pvt. Ltd. announces the release of a market assessment report on the "Global Antisense Oligonucleotide Therapeutics Market- by Therapy (Monotherapy and Combination), Molecule Target Indication (DNA Molecule and RNA Molecule), Target Indication (Duchenne Muscular Atrophy, Spinal Muscular Atrophy, Familial Chylomicronemia Syndrome, Amyotrophic Lateral Sclerosis, Familial Partial Lipodystrophy, Hereditary Transthyretin-Mediated (hatter) Amyloidosis, Huntington's Disease
Antisense RNAi Therapeutics Market: Size, Share, and Trends Analysis
The antisense RNA interference (RNAi) therapeutics market represents a burgeoning sector within the pharmaceutical industry, offering innovative treatments for a wide range of diseases by modulating gene expression at the post-transcriptional level. Antisense RNAi therapeutics leverage the RNA interference mechanism to target specific messenger RNA (mRNA) molecules, thereby inhibiting the production of disease-associated proteins. As of [current year], the market for antisense RNAi therapeutics is experiencing rapid growth, driven by advancements
Antisense Oligonucleotide Therapeutics Market 2024-2031 | Exclusive Study Report
Antisense Oligonucleotide Therapeutics Market worth $ 64.64 Billion by 2030 - Exclusive Report by Insight Analytics Insight Analytics Pvt. Ltd. announces the release of a market assessment report on the "Global Antisense Oligonucleotide Therapeutics Market- by Therapy (Monotherapy and Combination), Molecule Target Indication (DNA Molecule and RNA Molecule), Target Indication (Duchenne Muscular Atrophy, Spinal Muscular Atrophy, Familial Chylomicronemia Syndrome, Amyotrophic Lateral Sclerosis, Familial Partial Lipodystrophy, Hereditary Transthyretin-Mediated (hatter) Amyloidosis, Huntington's Disease
Current Trends: Antisense & RNAi Therapeutics Market in-depth Analysis
The global antisense & rnai therapeutics market is estimated to surpass $2,252.6 million by 2027, exhibiting a CAGR of 8.4% from 2020 to 2027. The report offers a thorough analysis of global antisense & rnai therapeutics market with detailed study of various aspects of the market such as market dynamics, vital segments, major geographies, key players, and competitive landscape. The report provides a clear picture of the current market situation and future
Antisense Oligonucleotides Market Global Trends, Analysis and Forecast 2027
Antisense oligonucleotides (ASOs) are 15–25 nt oligonucleotides designed to tie complementary RNA targets for the degradation. They are synthesized so that they can be used to block disease processes by altering the synthesis of a specific protein. ASOs offers promising treatment options for a range of medical disorders. They facilitate the development of therapeutics affecting protein targets which cannot be treated with protein therapeutics. They can target a particular malfunctioning
Antisense Oligonucleotides Market Opportunity Analysis, 2026
Antisense oligonucleotides are short, single stranded RNA or DNA molecules. Antisense oligonucleotides do not modulate the activity of already formed proteins, however they act before proteins are produced at the level of messenger RNA in the cell. Antisense oligonucleotides is used in treatment of oncology, Central nervous system therapeutics, inflammation therapeutics, diabetes, asthma, hair loss, etc. Antisense oligonucleotides is also used in genomics. Some examples of antisense nucleotides are fomivirsen